These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 24115296)
1. Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. Blé M; Aguilera V; Rubín A; García-Eliz M; Vinaixa C; Prieto M; Berenguer M Liver Transpl; 2014 Jan; 20(1):25-34. PubMed ID: 24115296 [TBL] [Abstract][Full Text] [Related]
2. Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin. Giusto M; Rodriguez M; Navarro L; Rubin A; Aguilera V; San-Juan F; Ortiz C; López-Andujar R; Prieto M; Berenguer M Liver Transpl; 2011 Nov; 17(11):1318-27. PubMed ID: 21761553 [TBL] [Abstract][Full Text] [Related]
3. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients. Campos-Varela I; Castells L; Esteban JI; Bes M; Rodríguez-Frías F; Sapisochin G; Allende H; Charco R; Esteban R Transplantation; 2012 Feb; 93(4):450-3. PubMed ID: 22262129 [TBL] [Abstract][Full Text] [Related]
4. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C. Pillai AA; Lee VS; Wang E; Rinella ME; Levitsky J Transplant Proc; 2010 Nov; 42(9):3647-51. PubMed ID: 21094833 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes. Berenguer M; Ortíz-Cantó C; Abellán JJ; Aguilera V; Rubín A; Prieto M; López-Labrador FX J Clin Virol; 2012 Mar; 53(3):231-8. PubMed ID: 22222052 [TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases. Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137 [TBL] [Abstract][Full Text] [Related]
7. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585 [TBL] [Abstract][Full Text] [Related]
8. Achieving Sustained Virological Response in Liver Transplant Recipients With Hepatitis C Decreases Risk of Decline in Renal Function. Satapathy SK; Joglekar K; Molnar MZ; Ali B; Gonzalez HC; Vanatta JM; Eason JD; Nair SP Liver Transpl; 2018 Aug; 24(8):1040-1049. PubMed ID: 29573131 [TBL] [Abstract][Full Text] [Related]
9. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. Cardoso AC; Moucari R; Figueiredo-Mendes C; Ripault MP; Giuily N; Castelnau C; Boyer N; Asselah T; Martinot-Peignoux M; Maylin S; Carvalho-Filho RJ; Valla D; Bedossa P; Marcellin P J Hepatol; 2010 May; 52(5):652-7. PubMed ID: 20346533 [TBL] [Abstract][Full Text] [Related]
10. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin. Calmus Y; Duvoux C; Pageaux G; Wolf P; Rostaing L; Vanlemmens C; Botta-Fridlund D; Dharancy S; Gugenheim J; Durand F; Néau-Cransac M; Boillot O; Chazouillères O; Samelson L; Boudjema K; Samuel D J Hepatol; 2012 Sep; 57(3):564-71. PubMed ID: 22613001 [TBL] [Abstract][Full Text] [Related]
11. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839 [TBL] [Abstract][Full Text] [Related]
12. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Sharma P; Marrero JA; Fontana RJ; Greenson JK; Conjeevaram H; Su GL; Askari F; Sullivan P; Lok AS Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914 [TBL] [Abstract][Full Text] [Related]
13. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study. Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061 [TBL] [Abstract][Full Text] [Related]
14. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM; J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748 [TBL] [Abstract][Full Text] [Related]
15. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511 [TBL] [Abstract][Full Text] [Related]
16. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296 [TBL] [Abstract][Full Text] [Related]
17. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients. Aziz H; Raza A; Waheed Y; Gill U; Gill ML Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873 [TBL] [Abstract][Full Text] [Related]
18. Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study. Belhadj N; Houissa F; Elloumi H; Ouakaa A; Gargouri D; Romani M; Kilani A; Kochlef A; Kharrat J; Ghorbel A Tunis Med; 2008 Apr; 86(4):341-5. PubMed ID: 19476135 [TBL] [Abstract][Full Text] [Related]
19. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Yu ML; Lee CM; Chen CL; Chuang WL; Lu SN; Liu CH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Su WW; Lin CL; Yang HC; Chen PJ; Chen DS; Liu CJ; Hepatology; 2013 Jun; 57(6):2135-42. PubMed ID: 23322699 [TBL] [Abstract][Full Text] [Related]
20. Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. Giannelli V; Giusto M; Farcomeni A; Ponziani FR; Pompili M; Viganò R; Iemmolo RM; Donato MF; Rendina M; Toniutto P; Pasulo L; Morelli MC; De Martin E; Miglioresi L; Di Paolo D; Fagiuoli S; Merli M; Transpl Int; 2012 Apr; 25(4):448-54. PubMed ID: 22353419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]